BioDelivery Sciences International, Inc. revised earnings guidance for the full year 2021. For the year, the company expected Total Company Net Revenue to be in the range of $165 million to $167 million, compared to previous guidance of $162 million to $167 million.
BioDelivery Sciences International, Inc.
Equities
BDSI
US09060J1060
Pharmaceuticals
1st Jan change | Capi. | |
---|---|---|
+26.77% | 661B | |
+27.43% | 566B | |
-6.29% | 352B | |
+20.39% | 332B | |
+3.11% | 283B | |
+13.96% | 231B | |
+5.16% | 200B | |
-9.04% | 195B | |
-4.91% | 145B |